Alex Theventhiran, MD
Glaucoma Specialist · Philadelphia, PANPI 1831403278
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Glaukos Corporation at 25.6% of the total. Reporting peaked in 2022 at $1,042 and has fallen 91.9% since, to $84 in 2025.
Across 55 payments — averaging $73.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$1K
- Alcon$786
- Aerie Pharmaceuticals, Inc.$523
- Bausch & Lomb Americas Inc.$415
- Sight Sciences, Inc.$353
- NEW World Medical,inc.$242
- plus $697 from 6 others
What the payments were for
- Food & beverage$4,053100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 7 | $1,037 |
| Alcon | 7 | $786 |
| Aerie Pharmaceuticals, Inc. | 5 | $523 |
| Bausch & Lomb Americas Inc. | 12 | $415 |
| Sight Sciences, Inc. | 3 | $353 |
| NEW World Medical,inc. | 1 | $242 |
| AbbVie(2 entities) | 8 | $217 |
| Ivantis, Inc | 1 | $133 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $124 |
| Sun Pharmaceutical Industries Inc. | 6 | $117 |
| Novartis | 3 | $84 |
| Shire North American Group Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$485
- Rocklatan$485
- iStent inject W$467
- Tecnis IOL$371
- Hydrus Microstent$283
- iStent inject Trabecular Micro-Bypass Stent System$270
- KXL System$261
- Photrexa$261
- OMNI(R) SURGICAL SYSTEM (US)$255
- enVista MX60 IOL$253
- Kahook Dual Blade$242
- Streamline Surgical System$242
- Ahmed Glaucoma Valve$242
- IACCESS$206
- iDose$158
- Clareon$153
- Tecnis Simplicity$124
- AcrySof$111
- AcrySof IQ VIVITY IOL$108
How this compares
Too few glaucoma specialist providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 1,302 | $895,002 |
| RestasisCyclosporine | 850 | $755,129 |
| Cyclosporine | 254 | $158,887 |
| RhopressaNetarsudil Mesylate | 386 | $158,267 |
| LumiganBimatoprost | 211 | $95,631 |
| CombiganBrimonidine Tartrate/Timolol | 203 | $83,257 |
| Prednisolone Acetate | 927 | $51,193 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 138 | $29,678 |
| Latanoprost | 2,219 | $20,097 |
| Methazolamide | 49 | $11,971 |
| Alphagan PBrimonidine Tartrate | 22 | $11,253 |
| Restasis MultidoseCyclosporine | 14 | $11,041 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 57 | $10,951 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 683 | $10,026 |
| Ketorolac Tromethamine | 617 | $9,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P, Restasis Multidose | $217 | $956,3121,300 claims |
| Bausch & Lomb Americas Inc.Xiidra | $415 | $895,0021,302 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $523 | $166,933411 claims |
| AlconSimbrinza | $786 | $29,678138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Philadelphia
- Moon Jeong LeePhiladelphia$3K
- Monica ZhangPhiladelphia$2K
- Qi CuiPhiladelphia$1K
- Victoria AddisPhiladelphia$279
- Eve HigginbothamPhiladelphia$143
- Mehul NagarshethWyomissing$32K
- Ayan ChatterjeeKing Of Prussia$17K
- Abhishek NemaniWyomissing$10K
- Andrew WilliamsPittsburgh$4K
- Zachary NadlerAbington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.